Global Uveitis Market, By Type (Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Others), Diagnosis (Visual Acuity Test, Funduscopic Exam, Ocular Pressure, Slit Lamp Exam, Others), Treatment (Anti-inflammatory, Antibiotics, Immunosuppressive, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Uveitis Market Analysis and Size
The global uveitis market is expected to witness significant growth during the forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market. The growth of global uveitis market enhanced by the growing cases of glaucoma and rise in research and development activities conducted by many pharmaceuticals’ companies. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global uveitis market in the forecast period 2022-2029. The expected CAGR of global uveitis market is tend to be around 6% in the mentioned forecast period. The market was valued at USD 588 million in 2021, and it would grow upto USD 937.18 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Uveitis is the group of inflammatory disease that damages the eye tissue and produces eye swelling mainly uvea part. Uvea supplies blood to the retina, retains is the light sensitive part of the eye that focus the image on brain, due to this disease impaired vision or completely vision loss occurs. Symptoms of uveitis include eye redness & pain, light sensitivity, blurred vison, decreased vision. Patients with AIDS, psoriasis, tuberculosis, ulcerative colitis, sarcoidosis, rheumatoid arthritis are at higher risk to get eye disorders.
Uveitis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Others), Diagnosis (Visual Acuity Test, Funduscopic Exam, Ocular Pressure, Slit Lamp Exam, Others), Treatment (Anti-inflammatory, Antibiotics, Immunosuppressive, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Aerie Pharmaceuticals, Inc. (U.S.), Allergan (Ireland), Bausch Health (U.S.), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Fera Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), EyePoint Pharmaceuticals,Inc (U.S.) Amorphex Therapeutics Holdings, Inc (U.S.), Kubota Vision Inc (U.S.)., Alcon (Switzerland), Astellas Pharma Inc. (Japan), Bayer AG (Germany), Novartis AG (U.S.), Carl Zeiss Meditec AG (Germany), Nidek Co Ltd (India), Accutome,Inc (U.S.), AqueSys (U.S.), Iridex Corporation (U.S.)
|
|
Market Opportunities
|
|
Global Uveitis Market Dynamics
Drivers
- Increase in Geriatric Population
The geriatric population is expected to increase the patient population globally, which boots the global angiomyolipoma market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Rising Incidence of Eye Disorders
As per The College of Optometrists, the prevalence of anterior uveitis is 12 per 100,000 people in a year. According to the International Agency for the Prevention of Blindness, it is estimated that around 80 million people will suffer from glaucoma in 2020, a huge increase from 20 million recorded in 2010. In addition to this, over 8 million people were bilaterally blind due to glaucoma, which is expected to increase to over 14 million by 2022.
- Increasing Demand for Retail Pharmacies
The rise in the number of open angle glaucoma therapeutics delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global uveitis market over a forecast period.
- High Cost
The huge expenditure associated with uveitis medications surely hamper the market growth.
This global uveitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global uveitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Uveitis Market
COVID-19 has left an unparalleled global public health crisis that has impacted practically every aspect of the industries. Its long-term impacts are expected to boost the industry growth in the upcoming years. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.
In the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge future growth due to the demand for vaccine and treatment drugs for COVID-19. Thus, this will leave a significant impact on the uveitis market.
Global Uveitis Market Scope
The global uveitis market is segmented on the basis of type, diagnosis, treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Anterior Uveitis
- Intermediate Uveitis
- Posterior Uveitis
- Panuveitis
- Others
Diagnosis
- Visual Acuity Test
- Funduscopic Exam
- Ocular Pressure
- Slit Lamp Exam
- Others
Treatment
- Anti-inflammatory
- Antibiotics
- Immunosuppressive
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Uveitis Market Regional Analysis/Insights
The global uveitis market is analysed and market size insights and trends are provided by type, diagnosis, treatment, distribution channel and end-user as referenced above.
The major countries covered in the global uveitis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Europe has been witnessing a positive growth for global uveitis market throughout the forecasted period due to the presence of key manufacture of the product, high research and development and healthcare expenditure and skilled professionals.
North America dominates the market due to increased government awareness programs and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Uveitis Market Share Analysis
The global uveitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global uveitis market
Key players operating in the global uveitis market include:
- Aerie Pharmaceuticals, Inc. (U.S.)
- Allergan (Ireland)
- Bausch Health (U.S.)
- Merck & Co. Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Fera Pharmaceuticals (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- EyePoint Pharmaceuticals,Inc (U.S.)
- Amorphex Therapeutics Holdings, Inc (U.S.)
- Kubota Vision Inc (U.S.)
- Alcon (Switzerland)
- Astellas Pharma Inc. (Japan)
- Bayer AG (Germany)
- Novartis AG (U.S.)
- Carl Zeiss Meditec AG (Germany)
- Nidek Co Ltd (India)
- Accutome,Inc (U.S.)
- AqueSys (U.S.)
- Iridex Corporation (U.S.)
SKU-